CN104127487A - Drug for treating mink digestive tract diseases - Google Patents
Drug for treating mink digestive tract diseases Download PDFInfo
- Publication number
- CN104127487A CN104127487A CN201410361494.6A CN201410361494A CN104127487A CN 104127487 A CN104127487 A CN 104127487A CN 201410361494 A CN201410361494 A CN 201410361494A CN 104127487 A CN104127487 A CN 104127487A
- Authority
- CN
- China
- Prior art keywords
- parts
- mink
- digestive tract
- drug
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a drug for treating mink digestive tract diseases and belongs to the technical field of drugs for veterinary use. The drug is prepared from 10 parts by weight of gentamycin, 7-8 parts by weight of diphenoxylate, 8-10 parts by weight of radix astragali, 8-10 parts by weight of wrinkled giant hyssop, 5-6 parts by weight of radix bupleuri and the balance glucose. Individual use or combined use of radix astragali, wrinkled giant hyssop and radix bupleuri does not produce effects of treating mink digestive tract diseases but through combination with gentamycin, the mixed drug has a mink digestive tract disease cure rate of 73.5% and has curative effects obviously higher than effects of colistin sulfate. Through further use of a small amount of resveratrol and tetramethylpyrazine, a drug having a higher mink digestive tract disease cure rate is obtained.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of mink digestive tract disease, belong to veterinary drug technical field.
Background technology
In mink farming process, colibacillosis is a kind of common mink digestive tract disease; Colibacillosis is a kind of acute illness, suddenly heavily suffers from death in ermine 2-3 days.Because bacillus coli mostly is spontaneous infection, infectiousness is strong, and in digestive tract, useful microorganism is also suppressed in therapeutic process or kill, and the balance of normal microflora is damaged, thereby obstinate.In addition, stressors is many, causes the state of an illness sharply to increase the weight of, thereby has greatly increased this sick mortality rate.
Gentamycin is a kind of aminoglycoside antibiotics, and these product are applicable to sepsis, septicemia, central nervous system infection (comprising meningitis), urinary tract genital system infection, respiratory tract infection, gastrointestinal infection (comprising peritonitis), biliary tract infection, skin, skeleton, otitis media, the sinusitis due to bacillus pyocyaneus, Bacillus proteus (indole is positive and negative), escherichia coli, Klebsiella, Enterobacter, Serratia, citrobacter genus and staphylococcus (comprising penicillin resistant (G) and methicillin-resistant bacterial strain); Soft tissue infection's (comprising burn), listeriosis.
Diphenoxylate, name diphenoxylate, diphenoxylate, diarsed.For the derivant of Pethidine, alternative opium is used, clinical conventional its hydrochlorate; Its hydrochlorate is white crystalline powder, odorless.Be slightly soluble in water, be slightly dissolved in ethanol, be soluble in chloroform, be insoluble to ether, 220～226 ℃ of fusing points.This product can directly act on intestinal smooth muscle, by suppressing intestinal mucosa sensor, eliminates the wriggling reflection of local mucosa and weakens enterokinesia, the segmental that can increase intestinal is simultaneously shunk, make intestinal contents pass through to postpone, be conducive to the absorption of enteral moisture, show stronger anti-diarrhea effect.Heavy dose has sedation, produces sense of euphoria; The acute and chronic functional diarrhea causing for a variety of causes and chronic enteritis etc.
Inventor attempts gentamycin and diphenoxylate to use simultaneously, is used for the treatment of mink digestive tract disease.Through overtesting, find, the two uses and compares separately with using with the two, and the curative effect of escherichia coli type digestive tract disease is not had to significant difference.
Summary of the invention
The object of the invention is to improve gentamycin and the curative effect of diphenoxylate to mink colibacillosis.At present, Chinese medicine is more and more widely used in animal pharmaceuticals; So inventor expects adopting Chinese medicine and gentamycin, the same use of diphenoxylate, to improve the curative effect to mink colibacillosis.
The Radix Astragali: slightly warm in nature, sweet in the mouth, returns spleen, lung meridian; Function cures mainly: invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, the metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle is difficult bursts, and burst and do not hold back for a long time, blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes.
Herba Pogostemonis, removing dampness by means of aromatics Chinese medicine; Function: removing dampness by means of aromatics; Stomach function regulating preventing or arresting vomiting; Dispelling summer-heat from superficies of the body; Cure mainly: gastral cavity abdomen painful abdominal mass Min, the inappetence of retention of dampness in middle-JIAO, vomit, have loose bowels.
Radix Bupleuri: cold nature, bitter in the mouth, returns liver, gallbladder meridian; Function cures mainly: and in table solution, soothing the liver, yang invigorating.For cold, fever, alternate attack of chill and fever, distending pain in the chest and hypochondrium, menoxenia, uterine prolapse, proctoptosis.
By testing research, find by the Radix Astragali, Herba Pogostemonis, Radix Bupleuri separately or be used in conjunction with, mink digestive tract disease not to be had to therapeutic effect.And the decoction liquor of the Radix Astragali, Herba Pogostemonis, Radix Bupleuri and gentamycin and diphenoxylate are used simultaneously, can improve gentamycin and the diphenoxylate curative effect to mink digestive tract disease.
First technical scheme that can realize foregoing invention object provided by the invention is:
A medicine for the treatment of mink digestive tract disease, is prepared from by following raw material medicaments:
In every 100 parts of crude drug, contain: 10 parts of gentamycins, diphenoxylate 7-8 part, Radix Astragali 8-10 part, Herba Pogostemonis 8-10 part, Radix Bupleuri 5-6 part, surplus is glucose; Described part is weight portion.
Its preparation method is: after each component is pulverized, be mixed and made into powder; Or, after each component is pulverized, add adjuvant and make various dosage forms; Or, after the decoction liquor of Chinese medicinal components is wherein mixed with other components, add adjuvant and make various dosage forms.
This medicine is 73.5% to the cure rate of mink digestive tract disease, use and compare individually or simultaneously with diphenoxylate with gentamycin, its curative effect be improved significantly.But the therapeutic effect of this medicine still has much room for improvement.
Resveratrol, Chinese another name: Resveratrol; Resveratrol; Stilbene triphenol; Resvertrol; 3,4', 5-trihydroxy stilbene; Resveratrolk; (E)-5-[2-(4-hydroxyphenyl)-vinyl]-Resorcinol.Being a kind of biological very strong natural polyphenol class material, being called again resvertrol, is the chemopreventive agent of tumor, is also to reducing platelet aggregation, the chemopreventive agent of prevention and treatment atherosclerosis, cardiovascular and cerebrovascular disease; There is antiviral and immunoregulation effect.
Tetramethylpyazine has pair antiadrenergic drug and potassium chloride to cause the effect that rabbit Arterial Rings In Vitro shrinks.Coronary flow be can obviously increase, arterial pressure and coronary resistance reduced.Can pass through blood brain barrier, rabbits after intravenous note can be observed Mesentery microcirculation blood flow rate and the open number of blood capillary increases, therefore there is the microcirculatory effect of enhancement.
At present, above-mentioned two kinds of materials are not all used to treat fur-bearing animal digestive tract disease, are not more used to treat mink digestive tract disease.Inventor can change its curative effect after surprisingly finding that resveratrol and tetramethylpyazine are added to said medicine of the present invention according to special ratios.By research experiment, find, with astragalus polysaccharides, agastache rugosa water extract, saikoside, replace " decoction liquor of being made by the Radix Astragali, Herba Pogostemonis, Radix Bupleuri " and then add after specified quantitative resveratrol and tetramethylpyazine, can further improve the therapeutic effect to mink digestive tract disease.
Second technical scheme that can realize foregoing invention object provided by the invention is:
A medicine for the treatment of mink digestive tract disease, is prepared from by following raw material medicaments:
In every 100 parts of crude drug, contain: 10 parts of gentamycins, diphenoxylate 7-8 part, astragalus polysaccharides 5-6 part, agastache rugosa water extract 3-4 part, saikoside 3-4 part, resveratrol 5-6 part, tetramethylpyazine 3-5 part, glucose surplus; Described part is weight portion.
Its preparation method is: crude drug is directly mixed and made into powder, or adds adjuvant to be prepared into various dosage forms after crude drug is mixed.
Wherein, described astragalus polysaccharides, is that the dry root of the Radix Astragali is through the water solublity heteropolysaccharide extracting, concentrated, purification forms; Described agastache rugosa water extract, be by Herba Pogostemonis decoct with water, filter, concentrate, dried product; Described saikoside, is Radix Bupleuri extract, [English name] Radix Stellaviae; [latin name] Radix Bupleuri.
Astragalus polysaccharides is faint yellow, and powder is fine and smooth, and tool draws moist.Astragalus polysaccharides is comprised of hexuronic acid, glucose, fructose, rhamnose, arabinose, galacturonic acid and glucuronic acid etc., can be used as immunopotentiating agent or regulator, there is the effects such as antiviral, antitumor, defying age, radioprotective, anti-stress, antioxidation simultaneously.
The consumption of medicine of the present invention: 1 adult mink takes the medicine that 0.1g crude drug is prepared into for 1 day; Administering mode: spice is fed, the medicine spice 200kg that 100g crude drug is prepared into.
the test of pesticide effectiveness
In Shandong plant, using U.S. sable as subjects, carry out the two-year test of pesticide effectiveness.During this period, concentrate and broke out 6 colibacillosiss (acute, subacute) altogether, have 396 minks ill.Each ill mink is equally divided into three groups, and wherein one group is matched group, and two groups is test group; The body weight, coincident with severity degree of condition, Symptoms and the feeding method that guarantee the mink of every group are consistent; Make every group of medication drug effect afterwards there is comparability.
The symptom of colibacillosis: their early stage, loss of appetite, listless, fervescence, asoscope is dry, and watery diarrhea and hemafecia, appear dysentery, in loose and watery stool soft yellow or the Lycoperdon polymorphum Vitt of being then, myasthenia of limbs, has a delicate constitution, the back of a bow of bending over, and around fecal pollution is serious for anus;
Cuing open inspection changes: acute, subacute disease ermine is cutd open the enlargement of the visible spleen congestion of inspection; The congested swelling of gastric mucosa, intestinal conjunctival congestion swelling; There is little petechia, present Catarrhal hemorrhagic enteritis and change; Lymphadenectasis, sometimes visible little petechia; The sick ermine of chronic process, gastric contains mucus, mucosa swelling, with most aphtha focuses and single petechia.In intestinal, contain large lead or the yellow-gray mucus of obtaining, mucosa swelling, has single or multiple petechias; The remarkable enlargement of mesenteric lymph node, tangent plane hyperemia and hemorrhage; Liver enlargement a little, lark, splenomegaly 2-3 doubly, has point-like hemorrhage.
Diagnosis: diagnose according to epidemiology, characteristics of incidence, clinical symptoms, pathological anatomical change.
Treatment:
Matched group, is used gentamycin and diphenoxylate spice to feed (18g medicine spice 200kg), and every ermine is fed the spice containing 0.05g gentamycin and 0.04g diphenoxylate at every turn, feeds every day 2 times.
Test group 1, is used the medicine spice of embodiment 1 preparation to feed (100g medicine spice 200kg), and every ermine is fed the spice containing 0.05g medicine at every turn, feeds every day 2 times.
Test group 2, is used the medicine spice of embodiment 2 preparations to feed (100g medicine spice 200kg), and every ermine is fed the spice containing 0.05g medicine at every turn, feeds every day 2 times.
Curative effect:
Recovery from illness: symptom disappears completely;
Effective: fervescence, asoscope are dry, soft yellow or Lycoperdon polymorphum Vitt, the dysentery of being of loose and watery stool, watery diarrhea and hemafecia, the back of a bow of bending over, anus be the transference cure of fecal pollution around, but, the phenomenon that still have loss of appetite, listless, myasthenia of limbs, has a delicate constitution.
Invalid: symptom is not improved completely, finally causes death.
Responding time: the meansigma methods of time used when the mink of final recovery from illness reaches " effectively " curative effect;
The course for the treatment of: the mink of final recovery from illness, the meansigma methods of the time used of fully recovering from taking medicine to.
After medication 1 day, therapeutic effect is as shown in table 1;
Table 1
| ? | Recovery from illness | Effectively | Invalid | Dead |
| Test group 1(132 only) | 8 | 66 | 51 | 7 |
| Test group 2(132 only) | 18 | 78 | 36 | 0 |
| Matched group (132) | 0 | 52 | 68 | 12 |
After medication 3 days, therapeutic effect is as shown in table 2;
Table 2
| ? | Recovery from illness | Effectively | Invalid | Dead |
| Test group 1(132 only) | 65 | 32 | 16 | 19 |
| Test group 2(132 only) | 82 | 37 | 5 | 8 |
| Matched group (132) | 34 | 39 | 28 | 31 |
(medication 7-10 days) is as shown in table 3 for the final curative effect of each medicine:
Table 3
| ? | Cure rate | Responding time | The course for the treatment of |
| Test group 1(132 only) | 73.5％ | 1.47 my god | 3.5 my god |
| Test group 2(132 only) | 90％ | 1.38 my god | 3.32 my god |
| Matched group (132) | 56.8％ | 1.58 my god | 4.1 my god |
The specific embodiment
Embodiment 1
Get gentamycin 10g, diphenoxylate 7g, Radix Astragali 8g, Herba Pogostemonis 10g, Radix Bupleuri 5g and glucose 60g mix homogeneously, grind to form powdery, obtain powder; This powder is the medicine for the treatment of mink digestive tract disease of the present invention.
Embodiment 2
By gentamycin 10g, diphenoxylate 8g, astragalus polysaccharides 5g, agastache rugosa water extract 4g, saikoside 3g, resveratrol 6g, tetramethylpyazine 5g and glucose 59g mix homogeneously, grind to form powdery, obtain powder; This powder is the medicine for the treatment of mink digestive tract disease of the present invention.
Embodiment 3
Get Radix Astragali 10g, Herba Pogostemonis 8g, Radix Bupleuri 6g, add the decoction liquor that water is made, then that decoction liquor is concentrated, dry, then mix with gentamycin 10g, diphenoxylate 8g and 58g glucose, grind to form powdery, obtain powder; This powder is the medicine for the treatment of mink digestive tract disease of the present invention.
Claims (3)
1. a medicine for the treatment of mink digestive tract disease, is prepared from by following raw material medicaments:
In every 100 parts of crude drug, contain: 10 parts of gentamycins, diphenoxylate 7-8 part, Radix Astragali 8-10 part, Herba Pogostemonis 8-10 part, Radix Bupleuri 5-6 part, surplus is glucose; Described part is weight portion.
2. a medicine for the treatment of mink digestive tract disease, is prepared from by following raw material medicaments:
In every 100 parts of crude drug, contain: 10 parts of gentamycins, diphenoxylate 7-8 part, astragalus polysaccharides 5-6 part, agastache rugosa water extract 3-4 part, saikoside 3-4 part, resveratrol 5-6 part, tetramethylpyazine 3-5 part, glucose surplus; Described part is weight portion.
3. medicine according to claim 2, it is characterized in that, by 10 parts of gentamycins, 8 parts of diphenoxylates, 5 parts of astragalus polysaccharidess, 4 parts of agastache rugosa water extracts, 3 parts of saikosides, 6 parts of resveratrols, 5 parts of tetramethylpyazines and 59 parts of mix homogeneously of glucose, grind to form powdery, obtain powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410361494.6A CN104127487A (en) | 2014-07-28 | 2014-07-28 | Drug for treating mink digestive tract diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410361494.6A CN104127487A (en) | 2014-07-28 | 2014-07-28 | Drug for treating mink digestive tract diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104127487A true CN104127487A (en) | 2014-11-05 |
Family
ID=51800509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410361494.6A Pending CN104127487A (en) | 2014-07-28 | 2014-07-28 | Drug for treating mink digestive tract diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127487A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700025738A1 (en) * | 2017-03-08 | 2018-09-08 | Univ Degli Studi Di Siena | Pharmaceutical composition comprising resveratrol and polymyxins for use as an antibacterial agent |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396443A (en) * | 2007-09-30 | 2009-04-01 | 天津瑞普生物技术集团有限公司 | Traditional Chinese medicine oral liquid for treating livestock and poultry alimentary tract disease |
| CN103585599A (en) * | 2013-11-06 | 2014-02-19 | 青岛农业大学 | Veterinary medicine for treating animal digestive tract diseases |
| CN103783286A (en) * | 2014-01-13 | 2014-05-14 | 河北科技师范学院 | Chinese herbal medicine feed additive for preventing mink colibacillosis |
-
2014
- 2014-07-28 CN CN201410361494.6A patent/CN104127487A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396443A (en) * | 2007-09-30 | 2009-04-01 | 天津瑞普生物技术集团有限公司 | Traditional Chinese medicine oral liquid for treating livestock and poultry alimentary tract disease |
| CN103585599A (en) * | 2013-11-06 | 2014-02-19 | 青岛农业大学 | Veterinary medicine for treating animal digestive tract diseases |
| CN103783286A (en) * | 2014-01-13 | 2014-05-14 | 河北科技师范学院 | Chinese herbal medicine feed additive for preventing mink colibacillosis |
Non-Patent Citations (3)
| Title |
|---|
| 尹宝英等: ""中西医结合治疗仔猪秋冬季腹泻"", 《陕西农业科学》 * |
| 解庆东: ""川芎嗪在消化系统疾病中的应用"", 《时珍国医国药》 * |
| 魏拣选等: ""中西医结合治疗犊牛腹泻"", 《中国牛业科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201700025738A1 (en) * | 2017-03-08 | 2018-09-08 | Univ Degli Studi Di Siena | Pharmaceutical composition comprising resveratrol and polymyxins for use as an antibacterial agent |
| WO2018162551A1 (en) | 2017-03-08 | 2018-09-13 | Università Degli Studi Di Siena | Pharmaceutical composition comprising resveratrol and polymyxins for use as antibacterial agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102847021B (en) | Enema for treating ulcerative colitis and preparation method thereof | |
| CN102640884B (en) | Feed for treating mycoplasmal pneumonia of swine and preparation method | |
| CN104127487A (en) | Drug for treating mink digestive tract diseases | |
| CN105381300A (en) | Traditional Chinese medicinal preparation for preventing and treating swine fever | |
| CN111760004B (en) | Traditional Chinese medicine granules for preventing and treating livestock and poultry influenza and application thereof | |
| CN104739995A (en) | Pelvic inflammation treating traditional Chinese medicine free-sugar granules | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN103156961B (en) | Medicine composition used for treating common cold, wind cold, and lung and stomach heat stagnation | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN103110734B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN103120727B (en) | Traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| CN104095910A (en) | Drug for treating respiratory diseases of minks | |
| CN104096217B (en) | A kind of medicine treating mink escherichia coli type digestive tract disease | |
| CN101564453A (en) | Medicine for treating chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN104095928B (en) | Medicine for treating proteus mirabilis type digestive tract disease | |
| CN103816486A (en) | Traditional Chinese medicine preparation for treating acute and chronic hepatitis | |
| CN103463399A (en) | Medicament for treating infantile asthma and preparation method thereof | |
| CN103099812A (en) | Medicine for treating porcine reproductive and respiratory syndrome and preparation method thereof | |
| CN104208213B (en) | A kind of Chinese-western medicine preparation treating chicken coccidiosis and preparation method thereof | |
| CN103110737B (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and preparation method thereof | |
| CN102258620A (en) | Chinese medicinal injection for treating mixed infection of swine streptococcus and swine fever and preparation method thereof | |
| CN105920208A (en) | Medicinal composition for treating infantile wind-heat type common cold | |
| CN104083731A (en) | Medicament for preventing and treating mixed infection of domestic rabbits as well as preparation method and application thereof | |
| CN105687835A (en) | Traditional Chinese medicine formula for treating mania and preparation method of traditional Chinese medicine formula for treating mania | |
| CN113663024A (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141105 |